

**Division of Newborn Medicine APP Spring Pharmacology Conference**

March 24<sup>th</sup>, 2023

12p-3p

*Virtual Through Microsoft Teams*

**Conference Agenda:**

12pm-1pm:

**Neonatal Arrhythmias**

Title: Pharmacology and Application of Anti-Arrhythmic Drugs in the Neonate

Presenter: Tyler H. Harris, M.D. (Faculty, Attending) and Lindsey Haack, M.D. (Fellow)

Heart and Vascular Institute, Division of Pediatric Cardiology

Learning Objectives:

1. Understand the common arrhythmias of the neonate
2. Describe the classification system for Antiarrhythmic drugs (AADs)
3. Understand the indications and side effects of commonly used AADs in the neonate

1pm-2pm:

**Patent Ductus Arteriosus**

Title: Patent Ductus Arteriosus (PDA): Updates and Recent Literature...To Treat or Not To Treat, that is the Question

Presenter: Brian C. King, M.D. (Faculty, Attending)

Division of Newborn Medicine

Learning Objectives:

4. Review pharmacokinetics and pharmacodynamics of drugs used in neonates to close the patent ductus arteriosus
5. Discuss the benefits and pitfalls of common drugs used to close the PDA: indomethacin, ibuprofen and acetaminophen
6. Review most recent clinical trial data available and leading to the best, evidence-based medicine approach to the premature infant with PDA

2pm-3pm:

## Pharmacology & BPD

Title: Let's Have a Heart to Lung: Pulmonary Hypertension in Bronchopulmonary Dysplasia

Presenters: Jennifer Shenk, PharmD, BCPPS & Melinda Miller, PharmD, BCPS

Children's Hospital of Pittsburgh, Pharmacy

Learning Objectives:

7. Describe the incidence and underlying pathophysiology of pulmonary hypertension (PAH) in infants with bronchopulmonary dysplasia (BPD)
8. Review pharmacologic options for the treatment of acute and chronic PAH
9. Apply evidence-based recommendations to PAH patient scenarios

*Conference Adjournment: 3pm*

Required Statements:

TARGET AUDIENCE

Nurse Practitioner, Pharmacist, Physician, Physician Assistant, CRNA, all APPs.

Accreditation and Designation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician (CME)

The University of Pittsburgh designates this live activity for a maximum of 3.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE)

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.0 contact hours.

Pharmacy (CPE)

This knowledge-based activity provides 3.0 contact hours of continuing pharmacy education credit.

## Physician Assistant (AAPA)

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

## Disclaimer Statement

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

## Faculty Disclosure:

No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients to disclose.

Please also add the policy for recorded lectures:

ATTENTION: This meeting will be recorded. Pursuant to UPMC Policy No. HS-IS0241, no Confidential Information may be discussed during the meeting. Confidential Information includes: Protected Health Information; information about specific UPMC patients (de-identified or not), specific UPMC employees (de-identified or not) or specific UPMC Health Plan members (de-identified or not); UPMC's proprietary business information;

privileged communications between UPMC counsel and UPMC personnel;

POLICY HS-IS0241

PAGE 6

© 2022 UPMC All Rights Reserved

and information subject to a UPMC legal or contractual obligation.

If you choose to attend this meeting, you consent under the governing law to the recording. You will have no obligation to appear, speak, or participate in the meeting. You may mute your microphone and turn off your camera for the entirety of the meeting.